We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test to Diagnose Heart Attacks Can Be Misleading

By LabMedica International staff writers
Posted on 27 Mar 2019
The use of increasingly sensitive troponin assays for excluding or diagnosing acute myocardial infarction has become universal. More...
A diagnosis of acute myocardial infarction is defined, in the context of an appropriate clinical presentation, by a rise or fall in cardiac troponin concentration, now the gold standard biomarker.

Current guidelines recommend troponin tests to help exclude or diagnose a heart attack. Manufacturers of troponin tests provide a recommended level (known as the 99th percentile) based on values from a few hundred healthy individuals. This recommended level is used as the upper limit of normal (ULN). In other words, if the value of troponin is above the 99th percentile, that is considered to be abnormal, and would indicate a heart attack in appropriate clinical circumstances.

Cardiologists at the University Hospital Southampton (Southampton, UK) and their colleagues conducted a prospective, observational study of 20,000 consecutive patients aged at least 18 years in whom a biochemistry blood test was requested for clinical reasons by their supervising doctor at the institution, between June 29, 2017, and August 24, 2017. The study population consisted of outpatients and inpatients, attendees at the emergency department, elective and emergency admissions, and every specialty within the hospital. The median age was 61 ± 20 and 52.9% were women.

The scientists used the Access AccuTnI+3 assay, which is used in routine clinical practice at the hospital. They applied this assay to measure hs-cTnI concentrations in the study population. The manufacturer’s recommended 99th centile (ULN) is 40 ng/L, which is the level they use in routine clinical practice. The coefficient of variation of the assay is less than 10% at 40 ng/L; the limit of quantification (10% of the coefficient of variation) is 20 ng/L; the limit of detection is 8 ng/L; and the limit of blank is 5 ng/L. The hs-cTnI levels were measured using the Beckman Coulter DxI800 platform.

The team found that found that the 99th centile of troponin for the whole study population was 296 ng/L compared with the manufacturer's recommended level of 40 ng/L. One in 20 (1,080; 5.4%) of all 20,000 patients had a troponin level greater than 40 ng/L, but in most of these patients there was no clinical suspicion of a heart attack. Overall, 39% of all patients from the critical care units, 14% of all medical inpatients, and 6% of all patients from the emergency department had a troponin concentration greater than the recommended ULN.

The authors concluded that of 20,000 consecutive patients undergoing a blood test for any clinical reason at their hospital, one in 20 had an hs-cTnI greater than the recommended ULN. These data highlight the need for clinical staff to interpret hs-cTnI concentrations carefully, particularly when applying the recommended ULN to diagnose acute myocardial infarction, in order to avoid misdiagnosis in the absence of an appropriate clinical presentation. The study was published on March 13, 2019, in the journal the BMJ.

Related Links:
University Hospital Southampton


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.